Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Tax Provisions: 2014-2024

Historic Tax Provisions for Theravance Biopharma (TBPH) over the last 11 years, with Dec 2024 value amounting to $19.4 million.

  • Theravance Biopharma's Tax Provisions fell 345.80% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year increase of 191.94%. This contributed to the annual value of $19.4 million for FY2024, which is 227.09% up from last year.
  • As of FY2024, Theravance Biopharma's Tax Provisions stood at $19.4 million, which was up 227.09% from $5.9 million recorded in FY2023.
  • Theravance Biopharma's Tax Provisions' 5-year high stood at $19.4 million during FY2024, with a 5-year trough of -$8.5 million in FY2020.
  • Moreover, its 3-year median value for Tax Provisions was $5.9 million (2023), whereas its average is $8.4 million.
  • In the last 5 years, Theravance Biopharma's Tax Provisions plummeted by 63.16% in 2020 and then surged by 65,922.22% in 2023.
  • Yearly analysis of 5 years shows Theravance Biopharma's Tax Provisions stood at -$8.5 million in 2020, then soared by 97.65% to -$200,000 in 2021, then spiked by 95.50% to -$9,000 in 2022, then skyrocketed by 65,922.22% to $5.9 million in 2023, then skyrocketed by 227.09% to $19.4 million in 2024.